secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001213900-24-110169
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake director resigns; CEO, CSO, CFO each to receive $4M equity grants in Jan 2025
--------------------------------------------------------------------------------

- Dr. Kara Lassen resigns from Board effective Dec 31, 2024, due to new role at Roche Pharma; no dispute with Company.
- Board approved long-term incentive program with annual equity grants; employees may elect restricted stock awards or stock options.
- CEO Dr. Jorge Santos da Silva, CSO Dr. Kristian Reich, and CFO Matthias Bodenstedt each expected to receive $4M grant date fair value in Jan 2025, vesting over four years.
- Board size reduced from 7 to 6 directors following resignation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024110169/0001213900-24-110169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024110169/ea0225122-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-110169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer